A nutrition researcher with multiple retractions who unsuccessfully sued the Canadian Broadcasting Corporation (CBC) for libel has been charged with defrauding a state health insurance plan.
A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).
falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.
In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report.
Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.
Here’s a strange one: We discovered a paper about an antibiotic-resistant strain of bacteria that bore two retraction notices, and each provided a different reason for retraction. One alleged misconduct; that notice still appears now. The other — which has since disappeared — said the paper was submitted by mistake.
A cluster of papers by different authors has been retracted for sharing text, even though some papers were submitted at the same time.
How is that possible? A spokesperson for Springer told us that they have reason to believe a third-party company may have helped prepare the papers for publication, and in the process might have spread the material around to multiple manuscripts.
The details of the cluster are a bit perplexing, so bear with us. Two of the papers — that were published only months apart — have already been retracted, as we reported in April. Now, two other papers have been retracted from Molecular Biology Reports — and both notices cite the previously retracted papers. The new notices also say that there’s reason to believe that the peer-review process was compromised.
All papers conclude that a certain polymorphism could signal a risk for coronary artery disease among Chinese people.
A journal has retracted the results of a clinical trial comparing strategies for bladder tumors after the authors mischaracterized the way patients were assigned to each procedure.
In addition, the journal European Urology has pulled a string of correspondence between author Harry Herr at Memorial Sloan Kettering Cancer Center and an outside expert, who had questioned aspects of the study totally unrelated to the methodology, such as its generalizability.
A journal has retracted an abstract after discovering the author didn’t submit it — and also because it appears “highly similar” to a previous publication in Chinese.
The abstract was presented at the 2nd International Conference on Biomedicine and Pharmaceutics in 2014, and lists Qing Guo as the sole author, based Wuhan, China at the China University of Geosciences.
According to the retraction notice, published in the Journal of Investigative Medicine last December, the organizer of the conference discovered Guo hadn’t consented to publish the abstract — moreover, it appeared to overlap with another article in Chinese, written by different authors: Continue reading Journal pulls abstract author didn’t submit
Damien Hirst’s “Away From The Flock” — exhibited at Tate Britain, via Flickr Commons
The corresponding author of the study that detected toxic leaks from the work of prominent British artist Damien Hirst has now retracted it — but most of his co-authors disagree with the decision.
Tate and Hirst’s company, Science Limited, immediately objected to the results; we’ve obtained what appears to be letter from a lawyer for Science Limited to the corresponding author of the paper — Pier Giorgio Righetti of the Polytechnic University of Milan in Italy — saying it was “deeply concerned and troubled by the claims” in the paper.
After questions from a reader, researchers took a second look at their data about the effects of a vitamin A metabolite on tumor cells, and realized their key finding was inaccurate.
They’re now retracting the paper, from Molecular Medicine Reports, because it originally reported that higher concentrations of retinoic acid (RA) were more effective in curbing the proliferation of brain tumor cells. But it seems that the RA dose made less of a difference than they originally believed, according to the retraction notice:
A cancer researcher who tried to sue PubPeer commenters for criticizing his work has earned five more retractions, bringing his total to 18.
All of the new retractions for Fazlul Sarkar, formerly based at Wayne State University in Michigan, appear in the International Journal of Cancer. Allcite an institutional investigation, and relate to issues with images.
With 18 retractions, Sarkar has now earned a spot on our leaderboard.
We first encountered Sarkar when he subpoenaed PubPeer to reveal the names of anonymous commenters that potentially cost him a job at the University of Mississippi. Earlier this month, a Wayne State spokesperson confirmed to us that Sarkar has now retired from the university. (To get up to speed, check out our timeline on the major events in this case.)